Opus Genetics, Inc. - Common Stock (IRD)
1.0000
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 6th, 5:37 AM EDT
Detailed Quote
Previous Close | 1.000 |
---|---|
Open | - |
Bid | 0.9310 |
Ask | 1.000 |
Day's Range | N/A - N/A |
52 Week Range | 0.6500 - 1.560 |
Volume | 36 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 165,443 |
Chart
About Opus Genetics, Inc. - Common Stock (IRD)
Opus Genetics, Inc. is a biotechnology company focused on developing innovative gene therapies to treat rare and debilitating genetic disorders. The company is dedicated to leveraging advanced scientific approaches to address unmet medical needs, particularly in the realm of inherited retinal diseases. By harnessing the potential of gene editing and delivery technologies, Opus Genetics aims to restore vision and improve the quality of life for patients affected by these challenging conditions. Through its research and development initiatives, the company strives to bring transformative therapies to market, offering hope to individuals and families impacted by genetic illnesses. Read More
News & Press Releases

Unusual volume stocks are being observed in Tuesday's session.
Via Chartmill · June 3, 2025

As of June 2, 2025, Power Metallic Mines Inc. (TSXV: PNPN) (OTCQB: PNPNF) —formerly known as Power Nickel Inc.—presents a compelling opportunity for investors seeking exposure to the booming battery metals and critical minerals sector. With its flagship Nisk Project in Quebec and a series of transformative corporate developments, the company is strategically positioned for significant growth potential.
Via AB Newswire · June 2, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · March 21, 2025
Via Benzinga · March 18, 2025